Tradename: SHINGRIX

Proper Name: Zoster Vaccine Recombinant, Adjuvanted

Indication: To include data on safety and the immune responses to SHINGRIX when administered concomitantly with Pneumococcal Vaccine Polyvalent (Pneumovax 23), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (PREVNAR 13) or Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX), or following revaccination after vaccination with Zoster Vaccine Live (ZOSTAVAX). 

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

in adults aged 50 years and older.

in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

Limitations of Use:

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Approval Date: 05/22/2023

Manufacturer: GlaxoSmithKline Biologicals